Accueil   Diary - News   All news Novadiscovery announces key collaboration with Janssen France to provide in silico based decision support for clinical development

Novadiscovery announces key collaboration with Janssen France to provide in silico based decision support for clinical development

 

Lyon, France – 17 December 2020: Novadiscovery, a leading health tech company offering a best-inclass clinical trial simulation platform, Jinkō®, to predict drug efficacy and optimize clinical trial development, today announces that it has entered into a collaboration with Janssen France to provide in silico based decision support for its clinical development pipeline.


Novadiscovery is committed to working with forward-looking industry leaders to improve R&D productivity and maximize patient outcomes through disease modeling and simulation, ahead of human trials.


Regulatory agencies in the US and Europe are working to provide a framework for the expanded use of model-informed drug development (MiDD) to improve clinical trial efficiency and increase the probability of regulatory success.

 

Read the press release